WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
WuXi Biologics has announced an agreement with Candid Therapeutics granting Candid exclusive global rights to a preclinical trispecific T-cell Engager developed using WuXi's WuXiBody™ platform. Under the agreement, WuXi Biologics will receive an upfront payment plus development and sales milestones totaling up to $925 million along with royalties.
The collaboration marks WuXi's seventh global program for molecules discovery through their Research platform in 2024, with eligible near-term payments of around $140 million and total potential payments exceeding $2.3 billion. The WuXiBody™ platform has been upgraded to deliver customized multispecific antibodies, offering advantages like high expression yield, stability, good solubility, and expedited development timeframes of 6-18 months with reduced manufacturing costs.
WuXi Biologics ha annunciato un accordo con Candid Therapeutics che concede a Candid diritti globali esclusivi su un Engager T-cell trispecifico preclinico sviluppato utilizzando la piattaforma WuXiBody™ di WuXi. In base all'accordo, WuXi Biologics riceverà un pagamento iniziale più traguardi di sviluppo e vendite che ammontano fino a $925 milioni insieme a royalties.
Questa collaborazione segna il settimo programma globale di WuXi per la scoperta di molecole attraverso la propria piattaforma di ricerca nel 2024, con pagamenti a breve termine idonei di circa $140 milioni e pagamenti totali potenziali che superano $2.3 miliardi. La piattaforma WuXiBody™ è stata migliorata per fornire anticorpi multispecifici personalizzati, offrendo vantaggi come un'elevata resa espressiva, stabilità, buona solubilità e tempi di sviluppo accelerati di 6-18 mesi con costi di produzione ridotti.
WuXi Biologics ha anunciado un acuerdo con Candid Therapeutics que otorga a Candid derechos globales exclusivos sobre un Engager de células T trispecífico preclínico desarrollado utilizando la plataforma WuXiBody™ de WuXi. Según el acuerdo, WuXi Biologics recibirá un pago por adelantado más hitos de desarrollo y ventas que totalizan hasta $925 millones, junto con regalías.
Esta colaboración marca el séptimo programa global de WuXi para el descubrimiento de moléculas a través de su plataforma de investigación en 2024, con pagos a corto plazo elegibles de alrededor de $140 millones y pagos totales potenciales que superan $2.3 mil millones. La plataforma WuXiBody™ ha sido mejorada para ofrecer anticuerpos multispecíficos personalizados, ofreciendo ventajas como alta rentabilidad de expresión, estabilidad, buena solubilidad y plazos de desarrollo acelerados de 6 a 18 meses con costos de fabricación reducidos.
우시 생물학이 칸디드 치료법과의 계약을 발표했습니다. 이 계약으로 칸디드는 우시의 WuXiBody™ 플랫폼을 사용하여 개발한 전임상 삼중 특이적 T세포 엔게이저에 대한 전 세계 독점 권리를 부여받았습니다. 계약에 따라 우시 생물학은 선불금과 함께 최대 $925 백만에 달하는 개발 및 판매 마일스톤을 받을 것이며, 로열티도 포함됩니다.
이 협력은 2024년 우시의 분자 발견을 위한 제7차 글로벌 프로그램으로, 약 $140 백만에 달하는 단기 지급 요건과 총 잠재적 지급액이 $2.3 억을 초과합니다. WuXiBody™ 플랫폼은 맞춤형 다특이적 항체를 제공하도록 업그레이드되었으며, 높은 발현 수율, 안정성, 양호한 용해도, 6-18개월의 단축된 개발 기간, 제조 비용 절감을 포함한 장점을 제공합니다.
WuXi Biologics a annoncé un accord avec Candid Therapeutics accordant à Candid des droits mondiaux exclusifs sur un Engager T-cell trispecifique préclinique développé à l'aide de la plateforme WuXiBody™ de WuXi. En vertu de l'accord, WuXi Biologics recevra un paiement initial ainsi que des étapes de développement et de vente totalisant jusqu'à 925 millions USD ainsi que des redevances.
Cette collaboration marque le septième programme mondial de WuXi pour la découverte de molécules via leur plateforme de recherche en 2024, avec des paiements à court terme éligibles d'environ 140 millions USD et des paiements totaux potentiels dépassant 2,3 milliards USD. La plateforme WuXiBody™ a été améliorée pour fournir des anticorps multispecifiques personnalisés, offrant des avantages tels qu'un rendement d'expression élevé, une stabilité, une bonne solubilité et des délais de développement accélérés de 6 à 18 mois avec une réduction des coûts de fabrication.
WuXi Biologics hat eine Vereinbarung mit Candid Therapeutics angekündigt, die Candid weltweit exklusive Rechte an einem präklinischen trispezifischen T-Zell-Engager gewährt, der mit WuXis WuXiBody™-Plattform entwickelt wurde. Im Rahmen der Vereinbarung erhält WuXi Biologics eine Vorauszahlung sowie Entwicklungs- und Verkaufsmeilensteine, die insgesamt bis zu 925 Millionen USD betragen, sowie Lizenzgebühren.
Die Zusammenarbeit markiert WuXis siebtes globales Programm zur Entdeckung von Molekülen über ihre Forschungsplattform im Jahr 2024, mit potenziellen kurzfristigen Zahlungen von rund 140 Millionen USD und insgesamt möglichem Zahlungen von über 2,3 Milliarden USD. Die WuXiBody™-Plattform wurde verbessert, um maßgeschneiderte multispezifische Antikörper zu liefern, die Vorteile wie eine hohe Ausdrucksernte, Stabilität, gute Löslichkeit und verkürzte Entwicklungszeiten von 6-18 Monaten bei reduzierten Produktionskosten bieten.
- Agreement includes potential payments up to $925 million plus royalties
- Part of larger portfolio with $140 million in near-term payments and $2.3 billion total potential
- WuXiBody platform demonstrates technical advantages in multispecific antibody development
- Product still in preclinical stage, indicating long development timeline ahead
- Milestone payments contingent on development and sales success
Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBodyTM. WuXi Biologics is eligible to obtain an upfront payment, and development and sales milestones totaling up to
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We're glad to enable Candid to advance the progress of T-cell engagers through WuXiBodyTM. This collaboration not only showcases the platform's capabilities in trispecific discovery in addition to its well-validated bispecific discovery, but also reinforces WuXi Biologics' position as a preferred partner for pioneering next-generation modalities. With this collaboration, we have enabled seven global programs for molecules discovery through our Research (R) platform in 2024, and are eligible to receive around
"To further solidify our leadership position in T-cell engagers to deplete B cells for treatment of autoimmune and inflammatory diseases, this transaction uniquely positions us with three TCE programs targeting BCMA, CD20, and CD19 in or near clinical development. We are excited to further the advances made by WuXi Biologics and to unlock the full potential of this molecule." said Dr. Ken Song, Chairman, President and CEO of Candid.
Based on the widespread adoption of WuXiBodyTM platform in bispecific antibody discovery, WuXi Biologics has upgraded it to deliver transformative and customized multispecific antibodies, addressing the growing global demand for these complex molecules. WuXiBodyTM can effectively break through the discovery and CMC barriers for the development of many multispecific antibodies with high expression yield, high stability, good solubility, and easy purification to homogeneity, expedite the process by 6-18 months and significantly reduce manufacturing costs, limitations still faced by many other current multispecific platforms. WuXiBody™ platform enables almost any mAb sequence pairs to be assembled into multispecific constructs, which are expected to have low immunogenicity risk and longer in vivo half-life. WuXiBody™ platform also has a unique structural flexibility, which makes it convenient to build various formats with different combinations of valencies (1+1, 2+2, 1+1+2, etc.) to meet the requirements of different target biology.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
About Candid Therapeutics, Inc.
Candid Therapeutics is a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for B-cell depletion to treat autoimmune diseases. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in
WuXi Biologics Contacts | |
Business | Media |
Candid Therapeutics Contacts | |
Arvind Kush | |
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-announces-agreement-with-candid-therapeutics-on-trispecific-t-cell-engager-302343561.html
SOURCE WuXi Biologics
FAQ
What is the total value of the WuXi Biologics-Candid Therapeutics agreement?
How many global programs has WuXi Biologics enabled through its Research platform in 2024?
What are the key advantages of WuXi Biologics' WuXiBody platform?
What is the total potential payment value across WuXi Biologics' current research programs?
